{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.78","value":"41.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"}],"units":"Participants"}],"title":"Baseline Cushing QoL Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.63","value":"7.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"}],"units":"Participants"}],"title":"Change from Baseline in Cushing QoL Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"}],"units":"Participants"}],"description":"The Cushing QoL patient questionnaire, which evaluates the health-related QoL in patients with Cushing syndrome, comprises 12 questions, each with 5 possible answers. The total score ranges from 12-60, with a higher score indicating improvement in QoL. The Cushing QoL instrument addresses known problem areas associated with Cushing syndrome including trouble sleeping, wound healing/bruising, irritability/mood swings/anger, self-confidence, physical changes, ability to participate in activities, interactions with friends and family, memory issues, and future health concerns.","dispersionType":"Standard Deviation","groups":[{"description":"Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (OL Phase)"}],"paramType":"MEAN","populationDescription":"The analysis population was patients in the mITT-OL Population.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 22 (end of OL Phase)","title":"Change in Cushing QoL Normalized Total Score During the OL Phase","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"score on a scale"}